Moreover, the lack of effective systemic immunotherapies for rare histologic subtypes such as SMARCB1-deficient renal medullary carcinoma and collecting duct RCC represents an opportunity to explore the role of TIL therapy and other novel adoptive immune agents in these populations. This evidence concerns the gene SMARCB1 and kidney medullary carcinoma.